Logo image of ORMP

ORAMED PHARMACEUTICALS INC (ORMP) Stock Fundamental Analysis

NASDAQ:ORMP - Nasdaq - US68403P2039 - Common Stock - Currency: USD

2  -0.09 (-4.31%)

After market: 2.01 +0.01 (+0.5%)

Fundamental Rating

3

ORMP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While ORMP has a great health rating, there are worries on its profitability. ORMP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ORMP had positive earnings in the past year.
ORMP had a negative operating cash flow in the past year.
ORMP had negative earnings in 4 of the past 5 years.
ORMP had a negative operating cash flow in each of the past 5 years.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

ORMP has a better Return On Assets (2.70%) than 85.87% of its industry peers.
The Return On Equity of ORMP (2.85%) is better than 84.78% of its industry peers.
Industry RankSector Rank
ROA 2.7%
ROE 2.85%
ROIC N/A
ROA(3y)-12.5%
ROA(5y)-20.94%
ROE(3y)-13.31%
ROE(5y)-29.78%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORMP has been increased compared to 1 year ago.
ORMP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ORMP has a worse debt to assets ratio.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

ORMP has an Altman-Z score of 5.18. This indicates that ORMP is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.18, ORMP belongs to the best of the industry, outperforming 80.43% of the companies in the same industry.
ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.18
ROIC/WACCN/A
WACC8.93%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 27.08 indicates that ORMP has no problem at all paying its short term obligations.
ORMP's Current ratio of 27.08 is amongst the best of the industry. ORMP outperforms 96.20% of its industry peers.
ORMP has a Quick Ratio of 27.08. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ORMP (27.08) is better than 96.20% of its industry peers.
Industry RankSector Rank
Current Ratio 27.08
Quick Ratio 27.08
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 136.59% over the past year.
The Revenue for ORMP has decreased by -100.00% in the past year. This is quite bad
ORMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.37% yearly.
EPS 1Y (TTM)136.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-20.92%
Revenue growth 5Y-11.37%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORMP will show a very negative growth in Earnings Per Share. The EPS will decrease by -48.90% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-125.5%
EPS Next 2Y-83.96%
EPS Next 3Y-123.6%
EPS Next 5Y-48.9%
Revenue Next Year-100%
Revenue Next 2Y-12.95%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ORMP is valuated correctly with a Price/Earnings ratio of 13.33.
Based on the Price/Earnings ratio, ORMP is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
ORMP is valuated cheaply when we compare the Price/Earnings ratio to 29.75, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for ORMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 13.33
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as ORMP's earnings are expected to decrease with -123.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.96%
EPS Next 3Y-123.6%

More info and screens

0

5. Dividend

5.1 Amount

ORMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (3/3/2025, 5:25:33 PM)

After market: 2.01 +0.01 (+0.5%)

2

-0.09 (-4.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners19.13%
Inst Owner Change10.57%
Ins Owners13.23%
Ins Owner Change14.21%
Market Cap80.62M
Analysts43.33
Price Target3.32 (66%)
Short Float %0.69%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3531.37%
Min EPS beat(2)-9511.76%
Max EPS beat(2)2449.02%
EPS beat(4)3
Avg EPS beat(4)-1649.26%
Min EPS beat(4)-9511.76%
Max EPS beat(4)2449.02%
EPS beat(8)7
Avg EPS beat(8)-805.44%
EPS beat(12)8
Avg EPS beat(12)-539.39%
EPS beat(16)11
Avg EPS beat(16)-403.51%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-114.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 13.33
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)0.15
EY7.5%
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS3.88
TBVpS3.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.7%
ROE 2.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.5%
ROA(5y)-20.94%
ROE(3y)-13.31%
ROE(5y)-29.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.08
Quick Ratio 27.08
Altman-Z 5.18
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)479.31%
Cap/Depr(5y)487.59%
Cap/Sales(3y)17.18%
Cap/Sales(5y)11.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y-125.5%
EPS Next 2Y-83.96%
EPS Next 3Y-123.6%
EPS Next 5Y-48.9%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-20.92%
Revenue growth 5Y-11.37%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-12.95%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y39.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.22%
OCF growth 3YN/A
OCF growth 5YN/A